We performed a prospective , randomized , double-blind , placebo-controlled trial of adults with eosinophilic esophagitis given an antibody against IgE ( omalizumab , n = @ ) or placebo ( n = @ ) every @-@ weeks for @ weeks , based on weight and serum level of IgE .